| Project/Area Number |
26860100
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Shiga University of Medical Science |
|---|
Principal Investigator |
Hira Daiki 滋賀医科大学, 医学部, 特任助教 (50636959)
|
|---|
| Research Collaborator |
TERADA TOMOHIRO 滋賀医科大学, 医学部, 教授 (10324641)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 個別医療 / トファシチニブ / 薬物動態 / 関節リウマチ |
|---|
| Outline of Final Research Achievements |
The aim of the present study is to develop the individual dose of tofacitinib, which is a novel synthetic disease modifying anti-rheumatic drug (DMARD) that selectively inhibits Janus kinase (JAKs), particularly JAK1 and JAK3.
In the present study, a novel and simple HPLC-UV assay method for the estimation of tofacinib concentration has been developed and validated. Transport characteristics of ABCB1 (P-glycoprotein, P-gp) and ABCG2 (breast cancer resistance protein, BCRP) were assessed by HEK293 cells stably expressing ABCB1 and ABCG2. The cellular accumulation of tofacitinib in HEK293-ABCB1 and HEK293-ABCG2 were markedly decreased than that in HEK293 cell as a control. These findings suggest that pharmacogenomic analysis help to optimize the individual dose of tofacitinib.
|
